HEALTH (ALT)

KWN HEALTH

HEALTH (MSM)

GSK sees little prospect of U.S. generic Advair in 2016

After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics – but not just yet. Chief Executive Andrew Witty said on Wednesday that the chances of cheap copies of its highly profitable inhaled medicine reaching the world’s biggest market in 2016 were “vanishingly small”.

Over 120 die in Yemen as Houthis take key Aden district

By Mohammed Mukhashaf and Mohammed Ghobari ADEN/CAIRO (Reuters) – Yemen’s Houthi militia battled its way into Aden’s Tawahi district on Wednesday despite Saudi-led air strikes, strengthening its hold on the city whose fate is seen as crucial to determining the country’s civil war. The fighting across Yemen killed 120 people on Wednesday, mostly civilians, including at least 40 who were trying to flee the southern port city of Aden by

Health workers race to prevent Nepal measles outbreak

Health workers are rushing to vaccinate more than half a million children in Nepal as fears grow that last month’s massive earthquake has made youngsters more susceptible to disease. UNICEF has warned of a race against time to prevent a deadly outbreak of measles in the impoverished Himalayan nation following the April 25 quake that killed 7,652 people in Nepal. The UN children’s fund, the World Health Organization and the

Alexion bolsters rare disease drugs business with $8.4 billion deal

Drugmaker Alexion Pharmaceuticals Inc agreed to buy Synageva BioPharma Corp for $8.4 billion at a hefty premium to expand in the lucrative market for drugs that treat rare diseases. Makers of drugs that treat rare diseases are seen as attractive takeover targets because of their revenue-generating potential as they typically charge high prices for their products. With the deal, Alexion will have eight experimental rare disease drugs under its belt,

Alexion bolsters rare disease drugs business with $8.4 billion deal

Drugmaker Alexion Pharmaceuticals Inc agreed to buy Synageva BioPharma Corp for $8.4 billion at a hefty premium to expand in the lucrative market for drugs that treat rare diseases. Makers of drugs that treat rare diseases are seen as attractive takeover targets because of their revenue-generating potential as they typically charge high prices for their products. With the deal, Alexion will have eight experimental rare disease drugs under its belt,

Health workers race to prevent Nepal measles outbreak

Health workers are rushing to vaccinate more than half a million children in Nepal as fears grow that last month’s massive earthquake has made youngsters more susceptible to disease. UNICEF has warned of a race against time to prevent a deadly outbreak of measles in the impoverished Himalayan nation following the April 25 quake that killed 7,652 people in Nepal. The UN children’s fund, the World Health Organization and the